zts-20241111
0001555280false00015552802024-11-112024-11-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 11, 2024
Zoetis Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3579746-0696167
(State or other jurisdiction(Commission File(I.R.S. Employer
of incorporation)Number)Identification No.)
10 Sylvan Way
Parsippany
New Jersey
07054
(Address of principal executive offices)(Zip Code)

(973) 822-7000
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareZTSNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

                                     Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 11, 2024, Wafaa Mamilli, currently Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health, informed Zoetis Inc. (the “Company”) of her decision to leave the Company in early 2025 to pursue an external opportunity. Ms. Mamilli will continue as an employee of the Company until her departure. As a result of Ms. Mamilli’s planned departure, Keith Sarbaugh has been promoted to the role of Executive Vice President and Chief Digital & Technology Officer effective immediately. Mr. Sarbaugh will be responsible for the Company’s technology, digital, data and analytics strategy.

Item 8.01. Other Events.

On November 11, 2024, the Company also announced several additional leadership changes. Jamie Brannan, currently Executive Vice President and Group President International Operations, Aquaculture and Global Diagnostics, was appointed to a newly created role of Executive Vice President and Chief Commercial Officer, effective immediately. As Chief Commercial Officer, Mr. Brannan will oversee all commercial markets across the globe including oversight of commercial operations across the United States and all International markets.

In addition, Ester Banque, currently Executive Vice President and President, U.S. Operations, will leave the Company and pursue other opportunities. Ms. Banque will serve in an advisory capacity until early 2025 to ensure a smooth transition. Jared Shriver has been promoted to President, U.S. Operations, effective immediately. Mr. Shriver will report to Mr. Brannan.

The Company issued a press release announcing the leadership changes at the Company. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits

(d)    Exhibits
Exhibit No.Description
Press Release issued on November 11, 2024 regarding the leadership changes at the Company.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)




SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Zoetis Inc.
November 12, 2024By:/S/ ROXANNE LAGANO
Roxanne Lagano
Executive Vice President,
General Counsel & Secretary



EXHIBIT 99.1
image_0a.jpg

Media Contacts:
Investor Contacts:
Jennifer AlbanoSteve Frank
1-862-399-0810 (o)1-973-822-7141 (o)
[email protected][email protected]
Laura PanzaNick Soonthornchai
1-973-975-5176 (o)1-973-443-2792 (o)
[email protected]



ZOETIS APPOINTS JAMIE BRANNAN TO NEWLY CREATED CHIEF COMMERICAL OFFICER ROLE
New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations
PARSIPPANY, NJ – Nov. 11, 2024 – Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world’s leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company’s long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities.
Mr. Brannan, who is currently Executive Vice President and Group President International Operations, Aquaculture and Global Diagnostics, will assume his new role effective immediately. His expanded role includes oversight of commercial operations across the United States and all International markets.
“As we enter the next phase of accelerated growth driven by our innovative and market-leading portfolio, the creation of this role will optimize our commercial operations and best position Zoetis to identify and capitalize on new market opportunities and deliver an exceptional experience for our customers,” said Kristin Peck, Chief Executive Officer of Zoetis. “Jamie is a true enterprise leader who has built high-performing and customer-obsessed leaders and
1 |

teams. I am confident that Jamie will help Zoetis drive our next phase of growth and continue to deliver excellent performance across markets.”
Mr. Brannan said, “Taking on this new role as Chief Commercial Officer is an incredible honor. I’m excited to lead our global commercial teams as we continue to innovate and deliver outstanding value to our customers. Together, we’ll drive Zoetis’ growth strategy, enhance our market presence and ensure we remain at the forefront of animal health solutions worldwide.”
Additional Leadership Changes
At the same time, Zoetis is announcing the following additional leadership changes:
•Wafaa Mamilli, currently Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health, has informed the company of her decision to leave the organization in early 2025 to pursue an external opportunity. The company regrets her decision but is grateful she will remain at Zoetis until early 2025 to ensure a smooth transition. Since joining Zoetis in 2020, Ms. Mamilli has been instrumental in positioning Zoetis as a leader in technology, digital transformation, data analytics and AI within healthcare. She has also overseen two key international markets, China and Brazil, and the company’s precision animal health businesses with a relentless focus on advancing customer success and innovation.
•With Ms. Mamilli’s planned departure, Keith Sarbaugh has been promoted to Executive Vice President and Chief Digital & Technology Officer and will join the Zoetis Executive Team, effective immediately. In this role, Mr. Sarbaugh will be responsible for the company’s technology, digital, data and analytics strategy and continue to oversee its Customer Experience function. Mr. Sarbaugh joined Zoetis in March 2023, and previously served as Vice President and Chief Information Officer. He brings nearly 25 years of tech and digital leadership experience from roles in IT and Commercial teams at Biogen and Eli Lilly.
•Ester Banque, currently Executive Vice President and President, U.S. Operations, will transition out of her role and pursue other opportunities outside of Zoetis. The company is grateful for Ms. Banque’s contributions to Zoetis during her tenure, delivering above market performance in the U.S. business. She will serve in an advisory capacity until early 2025 to ensure a smooth transition.
2 |

•Jared Shriver has been promoted to President, U.S. Operations, effective immediately, reporting to Mr. Brannan. In his nearly 20-year tenure at Zoetis, Mr. Shriver has demonstrated exceptional leadership across various commercial roles within the organization. He has consistently driven performance, exceeding financial targets and fostering a culture of accountability, collaboration, and excellence in sales and marketing. Mr. Shriver most recently served as Senior Vice President of U.S. Livestock, Bio Devices, Equine, and Platinum Performance.
About Jamie Brannan
As a senior business leader in human and animal health for over a decade, Mr. Brannan has consistently demonstrated his ability to build diverse teams with the agility to adjust through fast, evolving business conditions across international markets. Since joining Zoetis in 2016, Mr. Brannan has demonstrated a proven track record of strong commercial leadership, disciplined financial performance and the development of high-performing teams.
He most recently served as Executive Vice President and Group President International Operations, Aquaculture and Global Diagnostics at Zoetis, with responsibility for commercial operations in over 100 international markets, the global aquaculture and diagnostic businesses. Previously, he was president, Zoetis International Operations from June 2021 until November 2022, and senior vice president of Zoetis’ Northern Europe Cluster from October 2016 until June 2021.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.




ZTS-COR
ZTS-IR
3 |